Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 452 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALS - Amyotrophic Lateral Sclerosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

NCT03954600
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NPT520-34 (125 mg), Placebos (125 mg)
Drug
Lead sponsor
Neuropore Therapies Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Study in ALS With Abatacept & IL-2

NCT06307301
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Abatacept Injection [Orencia] and Proleukin (aldesleukin)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessing Perceptual Effects of Interactive Tasks

NCT06828523
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Listener judgements of speech produced in different tasks
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 65 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Interactions Between PALS and Caregivers

NCT06819124
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Structured Communicative Interaction, Unstructured communicative interaction
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcome Assessment for AT & BCI

NCT07407725
View directory record Official record
Conditions
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Eye Tracker, Mouth Operated Joystick, Non-invasive electroencephalogram (EEG) Headset, Implantable Brain-Computer-Interface, Personal Assistive Technology, Voice Control
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Terminated No phase listed Observational

Neurogenic Dysphonia/Dysphagia Registry

NCT02493491
View directory record Official record
Conditions
Neurogenic Dysphonia, Neurogenic Dysphagia
Interventions
Not listed
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 8, 2026, 2:05 PM EDT
Not listed No phase listed Observational

A Study to Evaluate the Performance of a Diagnostic Test in ALS

NCT02759913
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Lumbar puncture
Procedure
Lead sponsor
Iron Horse Diagnostics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional

Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)

NCT02710110
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PowerLung trainer, Micro Mouth Pressure Meter, Pulmonary Function Testing, Videofluoroscopic swallowing study, Swallowing Quality of Life Questionnaire, Iowa Oral Pressure Instrument, Capsaicin
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 8, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuromuscular Ultrasound in ALS

NCT01785550
View directory record Official record
Conditions
ALS
Interventions
Ultrasound of nerve and muscle
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

NCT01753076
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ozanezumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

NCT02872142
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Albutein 5%, Plasma Exchange
Biological · Procedure
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
19 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

NCT00706147
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 8, 2026, 2:05 PM EDT
Active, not recruiting Phase 2 Interventional

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dazucorilant 300 mg, Dazucorilant 150 mg, Placebo, Dazucorilant
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • San Francisco, California • Neptune City, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041
View directory record Official record
Conditions
Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy
Interventions
Placement of the BrainGate2 sensor(s) into the motor-related cortex
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2038
U.S. locations
6
States / cities
Sacramento, California • Stanford, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Recruiting Early Phase 1 Interventional

Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

NCT07224269
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities
Interventions
Terazosine, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders

NCT02118805
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 8, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

NCT04288856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB078
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

NCT07625605
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions
The MIND diet
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Elizabethton, Tennessee • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 8, 2026, 2:05 PM EDT
Completed No phase listed Observational

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

NCT02686268
View directory record Official record
Conditions
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • Amherst, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 8, 2026, 2:05 PM EDT
Recruiting No phase listed Observational

Healing ALS Registry Observational Study (HAROS)

NCT07233148
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS)
Interventions
Education about treatment options, Dietary Supplements: Vitamins, Minerals, Herbs, etc., Meditation, Prayer, Talk Therapy, Affirmations, Journaling, etc., Diet, various diets will be observed, Exercise, physical therapy, occupational therapy, speech therapy, sauna, EMS, massage and other therapies, ALS medications and other medications, Physical and emotional support
Other · Dietary Supplement · Behavioral + 1 more
Lead sponsor
Healing Advocates Registry and Ministry
Other
Eligibility
18 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Park City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 8, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01089010
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
15
States / cities
Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 8, 2026, 2:05 PM EDT